SCHEMBL19397141

SCHEMBL19397141

C=C1O[C@@H](n2ccc3c(NC(=O)c4ccccc4)ncnc32)[C@@](O)(C#CC)[C@@H]1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 1/20 0.36
▸ PRMT5 O14744 2/20 0.35
▸ WDR77 Q9BQA1 2/20 0.35
▸ ADORA3 P0DMS8 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ AURKA O14965 3/20 0.34
▸ RPS6KB1 P23443 2/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ RET P07949 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ ADORA1 P30542 2/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ BRD4 O60885 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19379637 1.00 ADK (0.36) ADKPRMT5WDR77ADORA3NPSR1
SCHEMBL30745131 0.80 ADK (0.38) ADKPRMT5WDR77ADORA3NPSR1
SCHEMBL19397144 0.80 ADK (0.38) ADKPRMT5WDR77ADORA3NPSR1
SCHEMBL19379658 0.80 ADK (0.38) ADKPRMT5WDR77ADORA3NPSR1
SCHEMBL19379661 0.76 ADK (0.34) ADKPRMT5WDR77ADORA3RET
SCHEMBL19379639 0.76 ADK (0.34) ADKPRMT5WDR77ADORA3RET
SCHEMBL31228223 0.76 ADK (0.45) ADKPRMT5WDR77NPSR1BRD4
SCHEMBL31154632 0.74 ADORA3 (0.56) ADKPRMT5WDR77ADORA3ADORA1
SCHEMBL15960600 0.74 ADORA3 (0.56) ADKPRMT5WDR77ADORA3ADORA1
SCHEMBL19379649 0.73 ADK (0.42) ADKADORA3ADORA1ADORA2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988416-B2 Alkynyl nucleoside analogs as inhibitors of human rhinovirus NOVARTIS AG (CH) 2018-06-05 — — US disclosed
US-20170275329-A1 ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) 2017-09-28 — — US disclosed
US-20170275329-A1 ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275329-A1 ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS RNASEH1, ENTPD5, SARNP ADK 578/4885PRMT5 1834/4885WDR77 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback